WEBULL
News
RNAZ
8.61
-0.30%
-0.03
Weekly Report: what happened at RNAZ last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at RNAZ last week (1117-1121)?
Weekly Report · 11/24 09:24
TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer
Reuters · 11/17 13:05
Press Release: TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
Dow Jones · 11/17 13:01
Weekly Report: what happened at RNAZ last week (1110-1114)?
Weekly Report · 11/17 09:24
Weekly Report: what happened at RNAZ last week (1103-1107)?
Weekly Report · 11/10 09:24
Weekly Report: what happened at RNAZ last week (1027-1031)?
Weekly Report · 11/03 09:23
TransCode Therapeutics Amends Preferred Stock Designation
TipRanks · 10/27 13:28
Weekly Report: what happened at RNAZ last week (1020-1024)?
Weekly Report · 10/27 09:25
Weekly Report: what happened at RNAZ last week (1013-1017)?
Weekly Report · 10/20 09:24
TransCode Therapeutics Updates SEC Filing to Report CVR Agreement Effective Date and Change in Rights Agent
Reuters · 10/17 21:09
TransCode Therapeutics Completes Phase 1a Trial for TTX-MC138
TipRanks · 10/14 12:27
Transcode Therapeutics’ TTX-MC138 achieves safety endpoint in Phase 1a study
TipRanks · 10/14 12:15
TRANSCODE THERAPEUTICS INC - SAFETY PRIMARY ENDPOINT ACHIEVED IN PHASE 1A TRIAL - SEC FILING
Reuters · 10/14 12:13
TransCode Achieves Phase 1a Safety Milestone For TTX-MC138, Advancing To Phase 2a After Durability And Disease Control In Cancer Patients
Benzinga · 10/14 12:09
TransCode Therapeutics Advances TTX-MC138 to Phase 2a Trials After Positive Phase 1a Results in Metastatic Disease
Reuters · 10/14 12:06
Weekly Report: what happened at RNAZ last week (1006-1010)?
Weekly Report · 10/13 09:24
TransCode Therapeutics Acquires Polynoma and Secures Investment
Barchart · 10/09 09:20
Transcode Therapeutics Issues Correction to Series B Preferred Stock Price in SEC Filing
Reuters · 10/08 20:14
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout
Benzinga · 10/08 14:48
More
Webull provides a variety of real-time RNAZ stock news. You can receive the latest news about Transcode Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.